Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

NCT02453711 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of a once-daily medication called semaglutide in adults who are obese but do not have diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 957 people

Who can join Ages 18+ · all sexes

Timeline Started 2015-10 · est. completion 2017-04

Where 74 sites · Australia, Belgium, Canada, Germany, Israel, Russia, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02453711 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.

Treatments tested

semaglutide Drug

Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
liraglutide Drug

Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
placebo Drug

Once-daily subcutaneous (s.c., under the skin) administration.

Main thing measured	Relative Change in Body Weight (%)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02453711 ↗